✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE3
Participants
ALL
Age Range
18 Years+
About This Trial
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).
Who Can Join?
Inclusion criteria: * Diagnosis of ulcerative colitis (UC) established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of UC. * Moderately to severely active UC defined as baseline (Week 0) modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopy subscore obtained during central review of the screening video endoscopy * An endoscopy subscore >=2 as obtained during central review of the screening video endoscopy * Have had an inadequate initial response, loss of response, or intolerance to previous approved systemic therapies Exclusion criteria: * Isolated proctitis (UC limited to the rectum only or to less than [
⚠ Always speak to your doctor before applying to any clinical trial.
More Gut & Digestion Trials
Recruiting PHASE3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn’s Disease…
Recruiting PHASE3A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and…
Recruiting PHASE3A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely…